<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01050348</url>
  </required_header>
  <id_info>
    <org_study_id>09-004 / WPCI 2009-08</org_study_id>
    <nct_id>NCT01050348</nct_id>
  </id_info>
  <brief_title>To Investigate the Role of Upstream High Dose Statin in STEMI</brief_title>
  <acronym>IMPRES</acronym>
  <official_title>A Double Blinded Randomized Placebo Controlled Study: To Investigate the Role of Upstream High Dose Statin Treatment in Patients With ST Segment Elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Western Pennsylvania Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>West Penn Allegheny Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Western Pennsylvania Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blinded randomized placebo controlled trial investigating the role of
      upstream 80mg Atorvastastin-calcium in patients undergoing percutaneous intervention for
      acute STEMI.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiovascular event (MACE) defined as cardiovascular death, MI, or target revascularization 30 days post percutaneous intervention.</measure>
    <time_frame>15 and 30 days post revascularization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Any increase in mean peak values of CK-MB, troponin I and myoglobin greater than twice the upper limit after intervention.</measure>
    <time_frame>15 and 30 days post revascularization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any occurrence of major adverse cardiac events defined as death, MI, congestive heart failure, cardiogenic shock or need for unplanned revascularization within 24 hours after procedure or need for emergent CABG.</measure>
    <time_frame>15 and 30 days post revascularization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic side effects of current statin medication as described by adverse effects on consent form.</measure>
    <time_frame>Immediately post revascularization to 30 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Coronary Revascularization Outcome Questionnaire (CROQ-PTCA)</measure>
    <time_frame>15 and 30 days post revascularization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Atorvastatin calcium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive study medication upon admission to hospital prior to percutaneous intervention of the culprit artery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive study medication upon admission to hospital prior to percutaneous intervention of the culprit artery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin calcium</intervention_name>
    <description>Eligible patients will receive 80mgs of atorvastatin orally upon admission to hospital prior to percutaneous intervention of the affected artery. Dose of post-procedural statin will be at the discretion of the cardiologist.</description>
    <arm_group_label>Atorvastatin calcium</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inactive Placebo</intervention_name>
    <description>Eligible patients will receive a placebo orally upon admission to hospital prior to percutaneous intervention of the affected artery.</description>
    <arm_group_label>Sugar Pill</arm_group_label>
    <other_name>Placebo, Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Any patient of 25 to 90 years of age admitted or transferred to Western Pennsylvania
             Hospital or Allegheny General Hospital with a diagnosis of STEMI undergoing emergent
             percutaneous intervention (PCI) to the culprit coronary artery. STEMI is defined as
             greater than 1mm ST segment elevation on electrocardiogram.

          2. Elevated cardiac biomarkers (troponin-T &gt; 0.03ng/ml, CKMB&gt;5ng/mL, or ck&gt;170 U/l).

        Exclusion Criteria:

          1. Known history of liver disease defined as cirrhosis, alcoholic liver disease, Non
             alcoholic steatohepatitis, hepatitis or any causes of liver failure.

          2. Renal failure with creatinine &gt;3mg/dL

          3. Known history of liver or muscle disease such as rheumatologic myopathies, history of
             myositis, hepatitis, and hepatic cancer.

          4. Cardiovascular arrest and shock.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Venkatraman Srinivasan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West Penn Allegheny Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Western Pennsylvania Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2010</study_first_submitted>
  <study_first_submitted_qc>January 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2010</study_first_posted>
  <last_update_submitted>November 29, 2016</last_update_submitted>
  <last_update_submitted_qc>November 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

